Saltar al contenido
PivotalWire
Lunes 12 oct 2026SEC · NASDAQ biomédico

Portada›Miércoles 26 de noviembre de 2025

Biomédicas del NASDAQ ante la SEC, miércoles 26 de noviembre de 2025

Los 33 documentos que 30 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. BCAXBicara Therapeutics Inc.424B5Nueva emisión de acciones con precioEDGAR
  2. CMNDClearmind Medicine Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…covering the October 31, 2024 consolidated financial statements contains an explanatory paragraph that states that the Company’s recurring losses from operations and lack of sufficient resources raise substantial doubt about the entity’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty. Such financial statements are incorporated in this prospectus supplement by…
  3. ELABPMGC Holdings Inc.S-1/ACapacidad de emisión registrada (enmienda)EDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…containing a microorganism transformed with a vector expressing myostatin and activin A on the cell surface as an active ingredient Going Concern As of December 31, 2024, management has determined there is substantial doubt about the Company’s ability to continue as a going concern. The Company may need to obtain funds to support its working capital, the methods of which include, without limitation, the following: ● this offering; ● other available sources of financing (including…
    En el documentoContrasplit de accionestexto original ▸…Skincare. On November 13, 2024, PMGC Capital LLC (“PMGC Capital”) was incorporated under the laws of the state of Nevada, PMGC is the sole shareholder of PMGC Capital. On November 27, 2024, the Company completed a reverse stock split on a ratio of two hundred old shares of common stock for every one new post reverse split share of common stock. On March 10, 2025, the Company completed a second reverse stock split on a ratio of seven…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…does not purport to be complete and is subject to and are qualified in their entirety by a copy of the Northstrive Secondment Agreement, filed herein as Exhibit 10.32. 47 ● On April 24, 2025, the Company entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Univest Securities, LLC (“Univest”), under which the Company may issue and sell from time to time, shares of its common stock, par value $0.0001 per share, having an aggregate…
  4. ELABPMGC Holdings Inc.S-1/ACapacidad de emisión registrada (enmienda)EDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…containing a microorganism transformed with a vector expressing myostatin and activin A on the cell surface as an active ingredient Going Concern As of December 31, 2024, management has determined there is substantial doubt about the Company’s ability to continue as a going concern. The Company may need to obtain funds to support its working capital, the methods of which include, without limitation, the following: ● this offering; ● other available sources of financing (including…
    En el documentoContrasplit de accionestexto original ▸…Skincare. On November 13, 2024, PMGC Capital LLC (“PMGC Capital”) was incorporated under the laws of the state of Nevada, PMGC is the sole shareholder of PMGC Capital. On November 27, 2024, the Company completed a reverse stock split on a ratio of two hundred old shares of common stock for every one new post reverse split share of common stock. On March 10, 2025, the Company completed a second reverse stock split on a ratio of seven…
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…does not purport to be complete and is subject to and are qualified in their entirety by a copy of the Northstrive Secondment Agreement, filed herein as Exhibit 10.32. 54 ● On April 24, 2025, the Company entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Univest Securities, LLC (“Univest”), under which the Company may issue and sell from time to time, shares of its common stock, par value $0.0001 per share, having an aggregate…
  5. HINDVyome Holdings, Inc424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…Haskell & White LLP, an independent registered public accounting firm, as stated in their report thereon (which report expresses an unqualified opinion and includes an explanatory paragraph relating to substantial doubt about ReShape Lifesciences Inc’s ability to continue as a going concern), and incorporated by reference in this Prospectus and Registration Statement in reliance upon such report and upon the authority of such firm as experts in accounting and auditing. The consolidated financial…
    En el documentoContrasplit de accionestexto original ▸…with the Company. The Selling Stockholders’ resale of these shares is registered on the registration statement of which this prospectus forms a part. Reverse Stock Split On August 15, 2025, the Company effected a 1-for-4 reverse stock split of its Common Stock (the “Reverse Stock Split”). On July 24, 2025, the stockholders of the Company approved the proposal to authorize the Board of Directors of the Company (the “Board”), in its discretion…
  6. JUNSJUPITER NEUROSCIENCES, INC.S-1Capacidad de emisión registradaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…price of our common stock could be subject to rapid and substantial volatility; and ● Our management’s assessment of historical losses, negative cash flows, and reliance on private equity financing raises substantial doubt about our ability to continue as a going concern, as noted in our auditor’s reports for the fiscal years ended December 31, 2023 and 2024. ● The other risk and uncertainties discussed in “Risk Factors,” elsewhere in this Registration Statement on Form…
    En el documentoContrasplit de accionestexto original ▸…incentive plans. On November 11, 2021, the Company increased the number of authorized shares of common stock, $0.0001 par value per share, to 45,000,000 from 25,000,000. On January 25, 2022, the Company effected a one-for-two (1:2) reverse stock split whereby the Company (i) decreased the number of issued and outstanding shares of common stock, $0.0001 per share, from 13,076,608 to 6,538,304 and (ii) decreased by a ratio of one-for two (1:2) the number…
  7. KTTAPasithea Therapeutics Corp.S-1/ACapacidad de emisión registrada (enmienda)EDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…development and commercialization activities. 6 The report of our independent registered public accounting firms for the fiscal year ended December 31, 2024 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. Due to the uncertainty of our ability to meet our current operating and capital expenses, in its report on our audited annual financial statements as of and for the year ended December 31, 2024, our…
  8. NRSNNeuroSense Therapeutics Ltd.424B3Prospecto suplementario o de reventaEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…the December 31, 2024 consolidated financial statements contains an explanatory paragraph that states that the Company’s recurring losses and its expectation to incur significant additional losses raise substantial doubt about the entity’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty. 26 ENFORCEMENT OF CIVIL LIABILITIES We are incorporated under the laws of…
  9. NXTCNextCure, Inc.S-3Capacidad de emisión registradaEDGAR
    En el documentoContrasplit de accionestexto original ▸…text thereof, copies of each of which have previously been filed as exhibits to our filings with the SEC. Reverse Stock Split On July 14, 2025 at 12:01 am Eastern time (the “Effective Time”), the Company effected a one-for-twelve (1:12) reverse stock split (the “Reverse Stock Split”) of the Company’s common stock. The Reverse Stock Split affected all shares of Company’s common stock outstanding immediately prior to the Effective Time. No fractional shares…
  10. QUCYQuantum Cyber N.V.424B5Nueva emisión de acciones con precioEDGAR
  11. RDHLRedHill Biopharma Ltd.424B5Nueva emisión de acciones con precioEDGAR
  12. GNPXGenprex, Inc.S-1/ACapacidad de emisión registrada (enmienda)EDGAR
    En el documentoPrograma de venta continua de acciones (ATM)texto original ▸…Additionally, if the holders of Second Private Warrants exercise such warrants in full, we would receive additional net proceeds of approximately $6.1 million. At-The-Market Offering On December 13, 2023, we entered into an At The Market (“ATM”) Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, serving as agent (the “Agent”) with respect to an at-the-market offering program (the “2023 ATM Facility”) under which we may offer and…
  13. LXEOLexeo Therapeutics, Inc.424B3Prospecto suplementario o de reventaEDGAR
  14. PYXSPyxis Oncology, Inc.S-3Capacidad de emisión registradaEDGAR
  15. RGNXREGENXBIO Inc.S-3Capacidad de emisión registradaEDGAR
  16. RXRXRECURSION PHARMACEUTICALS, INC.424B7Prospecto de reventa de tenedoresEDGAR
  17. SILOSilo Pharma, Inc.424B3Prospecto suplementario o de reventaEDGAR
  18. SNYRSynergy CHC Corp.S-3Capacidad de emisión registradaEDGAR

Participaciones y control

  1. CNTBConnect Biopharma Holdings LtdSC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

  1. AKTXAkari Therapeutics Plc8-KAviso de incumplimiento de cotizaciónEDGAR
  2. GNPXGenprex, Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
  3. GTBPGT Biopharma, Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
  4. HUMAHumacyte, Inc.8-KFin de acuerdo materialEDGAR
  5. MTVAMetaVia Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
  6. SHPHShuttle Pharmaceuticals Holdings, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
  7. TLRYTilray Brands, Inc.8-KCambio de estatutosEDGAR
    En el documentoContrasplit de accionestexto original ▸EX-99.1 3 ex_892350.htm EXHIBIT 99.1 EXHIBIT 99.1 Tilray Brands Announces Implementation of Previously Approved 1-for-10 Reverse Stock Split Common Stock Expected to Begin Trading on a Split-Adjusted Basis on December 2, 2025 NEW YORK – November 26, 2025 – Tilray Brands, Inc. (“Tilray Brands”, “Tilray” or “the Company”) (Nasdaq: TLRY; TSX…
  8. TPSTTempest Therapeutics, Inc.8-KVenta de acciones no registrada (colocación privada)EDGAR
  9. CGONCG Oncology, Inc.8-KCambio en el consejo o la direcciónEDGAR
  10. IMMXImmix Biopharma, Inc.8-KOtros hechos relevantesEDGAR
  11. IRWDIRONWOOD PHARMACEUTICALS INC8-KOtros hechos relevantesEDGAR
  12. RXRXRECURSION PHARMACEUTICALS, INC.8-KOtros hechos relevantesEDGAR
  13. TCRXTScan Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
  14. VERAVera Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.